RemeGen Co., Ltd. (Stock Code: 9995) approved a resolution on March 27, 2025, authorizing the use of up to RMB500 million of idle self-owned funds for principal-guaranteed bank wealth management products. According to the latest announcement, RemeGen formalized an agreement on November 3, 2025, with Shanghai Pudong Development Bank (SPDB) Yantai Branch to purchase a product valued at RMB400 million.

Under the terms of this 25-day principal-guaranteed product, the expected annualized yield ranges among 0.7%, 1.65%, or 1.85%, and its linked target focuses on the EUR-USD exchange rate. RemeGen previously signed a separate RMB100 million principal-guaranteed agreement with the same bank on October 15, 2025. Due to aggregation rules, the current purchase will count together with the earlier agreement and constitutes a discloseable transaction under Chapter 14 of the Listing Rules, triggered by exceeding the 5% threshold while remaining under 25%.

RemeGen highlighted that this use of idle self-owned funds aims to secure reasonable capital gains and maintain low risk. The board of directors considers these terms fair and in the interests of the company and its shareholders. RemeGen is a biopharmaceutical company specializing in innovative treatments for autoimmune, oncology, and ophthalmic diseases in China and internationally.